| Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents MR Hanselin, JJ Saseen, RR Allen, JC Marrs, KV Nair Hypertension 58 (6), 1008-1013, 2011 | 93 | 2011 |
| A review of the role of the pharmacist in heart failure transition of care SL Anderson, JC Marrs Advances in therapy 35, 311-323, 2018 | 76 | 2018 |
| Dapagliflozin for the treatment of type 2 diabetes SL Anderson, JC Marrs Annals of Pharmacotherapy 46 (4), 590-598, 2012 | 54 | 2012 |
| Spironolactone management of resistant hypertension JC Marrs Annals of Pharmacotherapy 44 (11), 1762-1769, 2010 | 39 | 2010 |
| Implementation of a clinical pharmacy specialist-managed telephonic hospital discharge follow-up program in a patient-centered medical home SL Anderson, JC Marrs, JP Vande Griend, R Hanratty Population health management 16 (4), 235-241, 2013 | 37 | 2013 |
| Board certification of pharmacist specialists ST Haines, MR Andrus, M Badowski, MM Bradbury, AE Canales, ... Pharmacotherapy 31 (11), 1146-1149, 2011 | 34 | 2011 |
| Bempedoic acid for the treatment of dyslipidemia JC Marrs, SL Anderson Drugs in context 9, 2020 | 30 | 2020 |
| How can clinical practices pragmatically increase physical activity for patients with type 2 diabetes? A systematic review KA Luoma, IM Leavitt, JC Marrs, AL Nederveld, JG Regensteiner, ... Translational Behavioral Medicine 7 (4), 751-772, 2017 | 30 | 2017 |
| Direct oral anticoagulants for the management of thromboembolic disorders: the importance of adherence and persistence in achieving beneficial outcomes A Amin, JC Marrs Clinical and Applied Thrombosis/Hemostasis 22 (7), 605-616, 2016 | 28 | 2016 |
| The NUDGE trial pragmatic trial to enhance cardiovascular medication adherence: study protocol for a randomized controlled trial RE Glasgow, CE Knoepke, D Magid, GK Grunwald, TJ Glorioso, ... Trials 22 (1), 528, 2021 | 24 | 2021 |
| Effects of lipid‐lowering therapy on reduction of cardiovascular events in patients with end‐stage renal disease requiring hemodialysis JC Marrs, JJ Saseen Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 30 (8 …, 2010 | 22 | 2010 |
| Proposed revision to the existing specialty and specialist certification framework for pharmacy practitioners MM Blair, RT Freitag, DL Keller, TH Kiser, JC Marrs, MS McGivney, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29 (4 …, 2009 | 21 | 2009 |
| Prevalence of and factors that influence board certification among pharmacy practice faculty at United States colleges and schools of pharmacy KA Toussaint, K Watson, JC Marrs, DA Sturpe, SL Anderson, ST Haines Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33 (1 …, 2013 | 20 | 2013 |
| Evaluation of statin prescribing for secondary prevention in primary care following new guideline recommendations JF Zupec, JC Marrs, JJ Saseen Annals of Pharmacotherapy 50 (1), 17-21, 2016 | 18 | 2016 |
| Ertugliflozin in the treatment of type 2 diabetes mellitus JC Marrs, SL Anderson Drugs in Context 9, 2020 | 17 | 2020 |
| Evidence and strategies for including emotional intelligence in pharmacy education L Butler, SK Park, D Vyas, JD Cole, JS Haney, JC Marrs, E Williams American Journal of Pharmaceutical Education 86 (10), ajpe8674, 2022 | 15 | 2022 |
| Indiplon: A Nonbenzodiazepine Sedative–Hypnotic for the Treatment of Insomnia JC Marrs Annals of Pharmacotherapy 42 (7-8), 1070-1079, 2008 | 15 | 2008 |
| Residents’ challenging role: Preceptee, preceptor, or both? JC Marrs, DM Rackham American Journal of Health-System Pharmacy 67 (3), 239-243, 2010 | 14 | 2010 |
| Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment SL Anderson, JC Marrs Drugs in Context 7, 2018 | 13 | 2018 |
| Antihyperglycemic medications and cardiovascular risk reduction SL Anderson, JC Marrs European Endocrinology 13 (2), 86, 2017 | 13 | 2017 |
